New Study Enrolling: RISE - Treating Ulcerative Colitis

AdventHealth Research Institute is the first in Central Florida to participate in the expansion phase of a clinical trial exploring a potential new oral immunotherapy treatment for mild to moderate ulcerative colitis. Called RISE-3750-01 and led by AdventHealth IBD Clinic Medical Director Jennifer Seminerio, MD, the study is evaluating the safety and tolerability of R-3750, which was designed to enhance the gut barrier, reduce inflammation and correct imbalance in the microbiota. Click below to learn more about this exciting study.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News

Advancing T1D Science: New TRI Publications

Researchers at the AdventHealth Translational Research Institute continue to drive meaningful progress in Type 1 diabetes—work that is being recognized not just in Central Florida, but throughout the...